Podcasts about cancer research aacr

Among the formerly undruggable targets gaining translational momentum, SMARCA2 has intrigued researchers for its potential to treat challenging solid tumors. On the latest BioCentury This Week podcast, BioCentury's editors zero in on preclinical research supporting different degraders of SMARCA2 at this year's American Association for Cancer Research (AACR) annual meeting.They also discuss takeaways from Editor in Chief Simone Fishburn's conversation with David Baker, the Nobel-prizewinning pioneer in protein design, and Steve Usdin reports that pharmaceutical industry executives are in a state of alarm over President Trump's push to include a “most favored nation” policy for Medicaid drug purchases in budget reconciliation legislation. Usdin also discusses why industry executives are confident of a fix for the Inflation Reduction Act's “pill penalty” and FDA Commissioner Marty Makary's decision to reject proposals to reorganize the agency. This episode was sponsored by Jeito Capital.View full story: https://www.biocentury.com/article/655851#biotech #biopharma #pharma #LifeScience #RandD #DrugDevelopment #AACR #SMARCA200:01 - Sponsor Message: Jeito Capital03:01 - AACR Spotlight11:21 - David Baker Protein Design19:12 - Trump's Drug Pricing PlanTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Loss of leadership, cuts to staffing and a proposed reorganization at FDA have heightened biotech risk amid an already turbulent macroeconomic climate, according to BioCentury's Washington editor Steve Usdin. On the latest BioCentury This Week podcast, BioCentury's editors discuss how the turmoil at FDA could affect a sector already grappling with the uncertainty brought by the Trump administration's trade war.The editors also explore the growing pipeline of VEGF-targeted bispecifics in a preview of upcoming presentations at annual meeting for the American Association for Cancer Research (AACR). And they discuss how companies may once again need to lean on their bear market survival toolkit, as part of BioCentury's 2Q25 Financial Markets Preview. This episode of BioCentury This Week was sponsored by RemeGen Co.View full story: https://www.biocentury.com/article/65556600:01 - Sponsor Message: RemeGen Co. 01:19 - FDA and Tariffs Turmoil16:54 - AACR Preview20:44 - Bear Market ToolkitTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

In this episode, Ayesha spoke with Mario Marcondes, MD, PhD, VP Head of Clinical Development at Nektar Therapeutics, a company focused on the discovery and development of novel therapies for autoimmune disorders and cancer. Dr. Marcondes is a licensed and trained physician, specializing in oncology and immune oncology. He has more than 15 years of research and teaching experience in Bone Marrow Transplant (BMT)/Cellular Therapies and more than 10 years of industry experience. He was the Program Lead for early-stage assets at Nektar and manages clinical trial programs from Phase I through to Phase III. Dr. Marcondes is a member of multiple professional clinical and translational research organizations, including the American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH), American Association for Cancer Research (AACR) and Center for International Blood & Marrow Transplant Research (CIBMTR). Listen to the episode to hear about the current research landscape in autoimmune disorders, including the work Dr. Marcondes is leading at Nektar Therapeutics. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

Send us a textMichael J. Burton is the CEO of the Diabetes Research Institute Foundation ( https://diabetesresearch.org/ ), a philanthropic organization which funds the Diabetes Research Institute, one of the largest and most comprehensive research centers dedicated to curing diabetes.A passionate nonprofit executive, Michael has more than 30 years of experience in leading high-impact philanthropic programs and cultivating strategic relationships to secure transformative funding. Prior to assuming the role of CEO at DRIF, Michael advanced the missions of some of the nation's most dynamic and trusted institutions including Princeton University, The Pew Charitable Trusts and the American Association for Cancer Research (AACR).Michael's accomplished nonprofit career includes significant contributions in the advancement of cancer research and care, most recently as President and CEO of Gateway for Cancer Research, a Chicago-based nonprofit engaged in funding early phase clinical research, where he began his tenure as Chief Development Officer. Prior to that, Michael served as Chief Development Officer and Executive Director of the Foundation at the AACR, the nation's oldest and largest organization dedicated to the prevention and cure of all cancers. Michael's 15 years of experience in the oncology sector also includes leading the development program at Fox Chase Cancer Center as Senior Vice President and Chief Development Officer.Before working in the field of oncology, Michael had a distinguished career in higher education, most notably at the University of Pennsylvania, where he served as Special Assistant to the President during the tenure of Judith Rodin, the first female president of an Ivy League institution; and at Temple University, where he held the title of Assistant Dean and lead the development program at the Fox School of Business. Before entering higher education, Michael served as Legislative and Press Assistant to the late Congressman Tom Lantos, the only survivor of the Holocaust ever elected to Congress. Michael is a graduate of the University of Pennsylvania, where he earned a Bachelor's degree in Communications and a Master's degree in Public Administration. Prof. Dr. Matthias von Herrath, MD is the Scientific Director of the Diabetes Research Institute (DRI) and Stacy Joy Goodman Chair at the University of Miami School of Medicine ( https://med.miami.edu/faculty/matthias-georg-von-herrath ) where he is leading the DRI mission to conduct and accelerate research to delay, prevent and ultimately find a cure for type 1 diabetes.  He is widely recognized for his groundbreaking work in understanding the molecular mechanisms of T1D, an autoimmune disease in which the body's immune system attacks and destroys insulin-producing beta cells in the pancreas, and developing novel therapies for this disease. Prof. Dr. von Herrath served as a Professor and Director for the Type 1 Diabetes Research Center at La Jolla Institute for Allergy and Immunology, and also currently serves as Vice President and Senior Medical Officer at Novo Nordisk, a global healthcare company, where he is responsible for overseeing the company's research and development efforts in diabetes care.Prof. Dr. von Herrath earned his medical degree in 1988 from Freiburg Medical School, where he also completed a Ph.D. equivalent thesis on biochemistry. His postdoctoral training included an intensive care residency at Diakonie Hospital, Freiburg.#DiabetesResearchInstituteFoundation #T1D #Insulin #IsletCellTransplant #Regeneration #Immunomodulation #Immunoregulation #Autoimmune #UniversityOfMiami #Philanthropy #NovoNordisk #Instacart  #ProgressPotentialAndPossibilities #IraPastor #PodcSupport the show

In this interview from the American Association for Cancer Research (AACR) 2024 Annual Meeting, Dr. Alankrita Taneja, third-year Hematology/Oncology Fellow at Roswell Park Cancer Institute and Oncology Data Fellows Forum Member, speaks with Dr. Sundar Jagannath, Professor of Medicine (Hematology and Medical Oncology) and Director of the Center of Excellence for Multiple Myeloma at the Mount Sinai Icahn School of Medicine and Tisch Cancer Institute. At the meeting, Dr. Jagannath presented results of the phase 1/2 LINKER-MM1 trial of linvoseltamab, a CD3-directed B-cell maturation antigen (BCMA) antibody under investigation for relapsed/refractory multiple myeloma. In this follow-up conversation, Dr. Jagannath shares further insights into the trial, including: • The study design, which includes triple-class–refractory patients • The unique dosing schedule of linvoseltamab, which reduces the frequency of administration to improve patient convenience • The response, survival, and measurable residual disease (MRD) negativity outcomes demonstrated in the trial, including among high-risk patients • Management of side effects, including cytokine release syndrome (CRS), neutropenia, anemia, and infections • The future role of linvoseltamab in the treatment landscape for relapsed/refractory multiple myeloma as it advances through investigation • And more!

Episode 17 (April 12, 2024): This week, the GEN editors discuss the launch of Nvelop Therapeutics, a new start-up leveraging approaches developed by gene editing pioneers David Liu, PhD, and J. Keith Joung, MD, PhD, to advance delivery of genetic cargo. The GEN editors also recap highlights from the American Association for Cancer Research (AACR) annual meeting held in San Diego, California. Featuring Uduak Thomas (Senior Editor, GEN), Alex Philippidis (Senior Business Editor, GEN), Julianna LeMieux, PhD (Deputy Editor-in-Chief, GEN), and Jonathan Grinstein, PhD (Senior Editor, GEN), and moderated by Fay Lin, PhD (Senior Editor, GEN Biotechnology) Listed below are key references to the GEN stories, media, and other items discussed in this episode of Touching Base: The State of Omics 2024 Registration GEN Summit Cloaking Device: Liu, Joung Launch $100M Nvelop Therapeutics to Advance Delivery of Genetic Cargo By Alex Philippidis, GEN Edge, April 9, 2024 Bertozzi, Regev, and More Inspire During the Opening Plenary Session of AACR By Julianna LeMieux, PhD, GEN, April 8, 2024 AACR 2024: Aviv Regev Shows How Single-Cell Atlases Foster New Axis to Genentech's Drug Discovery By Jonathan Grinstein, PhD, GEN, April 8, 2024 AACR 2024: A Video Update from San Diego By Julianna LeMieux, PhD, and Jonathan Grinstein, PhD, GEN, April 8, 2024 A Video Update from Day Two of the AACR Meeting By Julianna LeMieux, PhD, and Jonathan Grinstein, PhD, GEN, April 9, 2024 AACR 2024: EpiBiologics Advances Degraders of Membrane-Bound Proteins By Jonathan Grinstein, PhD, GEN, April 8, 2024 Celebrating National Robotics WeekBy Uduak Thomas, GEN, April 12, 2024 Hosted on Acast. See acast.com/privacy for more information.

This week, we cover key updates from the American Association for Cancer Research (AACR) 2024 Annual Meeting, held in San... The post Highlights from AACR 2024: KRYSTAL-1, FLAURA2, and EDGE appeared first on VJOncology.

Ishayu Chakroborty '24 was chosen as one of Mobile Bay's 2023 WONDER KIDS. During Project Engage Ish chose to do an internship with Dr. Grelet in the Department of Biochemistry and Molecular Biology at Mitchell Cancer Institute. Dr. Grelet specializes in tumor neurogenesis in cancer progression and metastasis with a focus on breast cancer. During the internship with Dr. Grelet, he was able to observe and assist with experimental lab work, as well as learn about bioinformatics and data analysis in biology, especially in breast cancer. The experience during Project Engage sparked his interest in cancer research and drove him to learn further about data analysis from publicly available datasets and repositories. The findings then led to a research project with guidance from Dr. Kakkat Ph.D. in the Department of Pathology at the Mitchell Cancer Institute. Because of his dedicated work in the research lab at the Mitchell Cancer Institute, Ish registered as a member of the American Association for Cancer Research (AACR) in the spring of 2022 and was invited to attend the AACR 2022 annual meeting in New Orleans [AS A JUNIOR IN HIGH SCHOOL!]. The American Association for Cancer Research (AACR) is the first and largest cancer research organization dedicated to accelerating the conquest of cancer. He then was contacted by Dr. Robin Felder, Director of Membership and Professional Development for AACR to complete the student registration form to attend the Special Program for High School Students entitled, "The Conquest of Cancer and the Next Generation of Cancer Researchers." He was then approached to present his research. Before Ish knew it, he had been vetted for membership and submitted the title of his research proposal for approval! American Association for Cancer Research had over 20,000 in attendance and Ish was ONE of only seven students in the United States who were invited to present their work/research at the meeting.

It is crucial to prioritize men's health during June Men's Health Month to raise awareness about the unique health challenges that men face and promote a proactive approach to their well-being. I speak to Dr. Neva White, Director of the Jefferson Collaborative for Health Equity and Executive Director of the Frazier Family Coalition for Stroke Education and Prevention about the resources available for men at through the Jefferson Collaborative for Health Equity.www.FrazierFamilyCoalition.org iHeartMedia's WDAS FM, Power 99 and Rumba 106.1 held our 6th annual Sista Strut Breast Cancer Walk to raise awareness about the impact of breast cancer in women of color. The American Association for Cancer Research was a beneficiary of the event. I speak to Dr. Camille Ragin is Associate Director of Diversity, Equity, and Inclusion and Professor in the Cancer Prevention and Control Program at Fox Chase Cancer Center – Temple Health System. Dr. Ragin is an Active member in the American Association for Cancer Research (AACR), the current Chair of the AACR-Minorities in Cancer Research (MICR) Council, and the 2023 recipient of the AACR-Team Science Award. We discuss the challenges of health disparities as it relates to Breast Cancer in Black women.www.aacr.org More than 25,000 Black/African Americans are diagnosed with seizures or epilepsy each year. In fact, Black/African Americans are more likely to be diagnosed with epilepsy than White Americans. For many Black/African Americans, stigma and access to appropriate care are major concerns. I speak to Rachel Robinson, Epilepsy Advocate, Epilepsy Foundation of Eastern Pennsylvania, who dispels misconception about the disease and resources and support available to people living with Epilepsy. ChangeOurStory.org Social Media: @EpilepsyFdn

I enjoyed a conversation with NFL Player and Super Bowl Champion, Rodney McLeod and wife Erika McLeod, Philanthropist and Healthcare and youth advocate about the fun and fabulous 3rd annual Sneaker Ball to benefit their Change Our Future Foundation Thursday June 22nd at Vie by Cescaphe. Listeners can take advantage of a ticket discount code: SBIHEART23https://www.givesignup.org/TicketEvent/ChangeOurFutureSneakerBall I speak with Wendy Williams, Program Analyst Supervision For The Public Awareness Unit for Philadelphia's Intellectual DisAbilities Services (IDS) about the 31st Annual Brighter Future Awards which honors those dedicated to improving the lives of individuals with intellectual disabilities. https://dbhids.org/event/31st-annual-my-city-my-place-brighter-futures-awards/ Philly's 105.3 WDAS FM, Power 99 and Rumba 106.1 are sponsoring the 6th Annual SISTA STRUT Breast Cancer Walk which takes place Saturday, June 17th at Xfinity Live! A portion of the proceeds go to the American Association for Cancer Research. The AACR has been a leader is examining health disparities in communities of color. I speak to Dr. Brian Rivers is Professor and Director of the Cancer Health Equity Institute at Morehouse School of Medicine (MSM) and a nationally and internationally recognized as a thought leader in health disparities research. Dr. Rivers is an Active member in the American Association for Cancer Research (AACR) community and has served in several leadership capacities.https://wdasfm.iheart.com/featured/sista-strut-philadelphia/https://www.aacr.org/ First, Kofi Asante Executive Producer and Artistic Director of Philadelphia Juneteenth Family Inc. tells us about a series of events to mark Juneteenth.https://www.facebook.com/phillyjuneteenth 267-721-3906

Discussing AACR 2023 Highlights - focusing on 3 studies that potentially could impact our practice in the community from this conference. - AEGEAN study for Non-Small Cell Lung Cancer - Keynote 966 for Cholangiocarcinoma - SWOG S1512 for Desmoplastic Melanoma

On this week's episode of Biotech Hangout, hosts Daphne Zohar, Josh Schimmer, Tim Opler, Michal Preminger and Brad Loncar discuss the latest industry news including deals and financings, data, regulatory and more. Brad starts the episode by sharing a personal update on the health of his father, thanking the biotwitter community and lauding the first responders, nurses and specialists who helped save him. Despite some industry setbacks from the week, there was positive news to share including data from a Torreya study, which showed the specialist buyside remained strong at the end of 2022 as well as a list of turnaround stories in the industry. The American Association for Cancer Research (AACR) released their 2023 abstract, sharing Moderna's personalized cancer vaccine study as a clear showstopper. Interesting news on the funding landscape, with 4 VCs announcing fundraises, while there was a huge drop in funding to companies. Following the overturning of the FDA's approval of mifepristone, Daphne joined over 400 others to sign a letter condemning the ruling & called for it to be overturned. *This episode aired on April 14, 2023* Disclosures from Josh Schimmer: "Disclosures for the stocks that I cover can be found on the Biotech Hangout home page."

Top 5 Most Read RNS's on Vox Markets for Monday 27th March 2023 5. Union Jack Oil #UJO - US$14m Net Revenues Landmark Reached at Wressle Landmark US$14,000,000 revenues generated to Union Jack since re-commencement of production at Wressle during August 2021. Union Jack holds a 40% economic interest in this development. Union Jack continues to be cash flow positive covering all G&A, OPEX and contracted or planned CAPEX costs, including any drilling activities for at least the next 12 months As of 24 March 2023, cash balances, short-term receivables and investments stood at over £10,500,000 & Debt free 4. Helium One Global #HE1 - Unaudited Interim Results Successfully raised £9.9 million ($12.3 million) in December to fund the Company through the 2023 Drilling programme in the Rukwa Basin, anticipated in 3Q 2023 Completion of analysis of Falcon Airborne Gravity Gradiometry and aero-magnetic data over the Balangida Basin; developing a greater understanding of rift geometry, basin evolution and subsurface structure for targeted exploration Net cash balance as at 31 December 2022 of $13.7 million 3. Gulf Keystone Petroleum #GKP - Update on Shaikan Field exports Gulf Keystone has noted reports that the long running arbitration case between Iraq and Turkey concerning the Iraq-Turkey export pipeline has been awarded in Iraq's favour. Subsequent to the Court's reported decision, the Kurdistan Pipeline Company notified GKP on 25 March that the Iraq-Turkey pipeline has been shut-in at Turkey's request until the situation is resolved. The KRG exports crude from the Shaikan Field and other fields in the region via this route. GKP's facilities have storage capacity that allow continued production at a curtailed rate over the coming days after which the Company will suspend production. 2. Canadian O'Seas Petr #COPL - Completion of US$14.8m Convertible Bond Financing Canadian Overseas Petroleum announce that it successfully completed its US$14.8 million convertible bond financing on March 24, 2023 with the full increase option being exercised. The Convertible Financing has been led by the main bondholder, institutional stakeholders, and new institutional investors providing the full amount of US$14.8 million principal, showing their strong support for the Company. 1. Avacta Group #AVCT - AVA3996 data poster presentation at AACR Avacta Group plc announces it will present a poster entitled 'AVA3996, a novel pre|CISION™ medicine, targeted to the tumor microenvironment via Fibroblast Activation Protein-alpha (FAP-a) mediated cleavage', at the American Association for Cancer Research (AACR) 2023 Annual Meeting, taking place at Orange County Convention Center, Orlando, Florida on 16 April.

Nancy Davidson, M.D., serves as the Executive Vice President for Clinical Affairs and Senior Vice President and Professor of the Clinical Research Division at the Fred Hutchinson Cancer Center at the University of Washington, where she heads the Division of Medical Oncology. She is the past President of both the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR). She is a recipient of a number of prestigious awards including the ASCO Gianni Bonadonna Breast Cancer Award and the NCI Rosalind E. Franklin Award and was recently inducted into the Giants of Cancer Care. “I don't think I can ever be a professor at Johns Hopkins,” said Dr. Davidson when she was a junior faculty to her mentor Dr. Martin Abeloff. He responded with three words she has taken to heart since: “Why ever not?” Tune into a conversation with Dr. Nancy Davidson, world-renowned breast cancer researcher and past president of both ASCO and AACR, on pushing beyond doubts and uncertainties, preserving the ‘One Community' mindset as we work in teams, and embracing the most effective mentoring relationship: Bidirectional. Pearls of Wisdom:   1. The central theme of our careers should be the patient. With every setback, failure, challenge, lost opportunity, and professional strife, we should try to reorient ourselves and bring our focus back to the patient's healthcare. 2. Mentorship is bidirectional. We will provide mentorship to people, but if we're smart and we listen well, some of the people that we are so-called mentors for will be teaching us all along the way. 3. Why ever not? An important question when we doubt ourselves. There is an element of resilience and recovery; not everything will go swimmingly in our career, but taking what we can learn from it will help us move forward. 4. All of us are looking for growth, but one thing that is essential is seizing the moment, and that involves saying yes and jumping on the opportunity when many times we are taught to say no.

Adriana Albini"Festival della Mente"Stile di vita e movimento per una vita sanahttps://www.festivaldellamente.it/it/Festival della Mente, SarzanaDomenica 4 settembre 2022, ore 12:00Adriana Albini"Stile di vita e movimento per una vita sana"Grazie alla ricerca siamo in grado di sconfiggere le malattie prima ancora che si presentino. Prevenire è meglio che curare, anche e soprattutto per quanto riguarda rischio cardiovascolare e tumori. Un buono stile di vita – non fumare, mangiare sano e non assumere peso, fare attività fisica e movimento – da solo può ridurre di molto il rischio di malattie complesse e le loro complicanze. La guerra che combattiamo contro il cancro è estremamente costosa e quindi discriminante tra strati sociali e aree geografiche. Se si arrivasse a ridurre il bisogno di cure, perché ci si ammala meno o si intercetta la malattia in tempo, la spesa farmaceutica diminuirebbe a vantaggio di quella preventiva, e il successo potrebbe essere eclatante.Adriana Albini è collaboratrice scientifica all'IRCCS Istituto Europeo di Oncologia (IEO) e docente di Patologia generale all'Università Milano Bicocca. È stata responsabile del Laboratorio di Biologia vascolare e Angiogenesi IRCCS MultiMedica di Milano e direttrice scientifica di MultiMedica Onlus. Si occupa di ricerca oncologica, immunologia, prevenzione farmacologica e con molecole di origine alimentare. Nel 2018 è stata eletta nel Board of Directors di AACR (American Association for Cancer Research) per il triennio 2018-2021. Inserita dalla BBC tra le 100 donne più influenti nel 2020, nel 2021 è stata nominata responsabile del nuovo Gruppo di Lavoro sulla Prevenzione Oncologica (Cancer Prevention Working Group- CPWG) dell'American Association for Cancer Research (AACR). Pratica scherma agonistica nei Master.IL POSTO DELLE PAROLEascoltare fa pensarehttps://ilpostodelleparole.it/

Each year, the Rally for Medical Research raises awareness of the urgent need for increased investment in the NIH to improve health, spur progress, inspire hope, and save lives. In collaboration with over 350 organizations, the Rally urges policymakers to make biomedical research a national priority. Now in its 10th year, we are proud to celebrate the critical advances made possible by the efforts of advocates nationwide. Joining us today for the conversation is Jon Retzlaff, Chief Policy Officer and VP of Science Policy and Government Affairs at the American Association for Cancer Research (AACR). Since launching the Rally in 2013, AACR has united thousands of Americans in one cause: the vital national importance of medical research.

This week, we invited on Tiah Tomlin-Harris, an overcomer of Triple Negative Breast Can't-cer, as she calls it, to discuss breast cancer awareness. Tiah has dedicated herself to being a community change agent and advocate, with a focus on health disparities, black women's health and healthy lifestyle education. As a result of her advocacy work, she has received recognition and awards, to include President Bush's – Point of Lights Award. Tiah is a Cancer Coach, a Breast Health Educator and a Project Lead graduate with the National Breast Cancer Coalition (NBCC). She has advocated for survivors on Capitol Hill; served as a board member and advisory board member for several organizations and pharmaceutical companies; published a research paper on Clinical Trials in Metastatic Breast Cancer; has spoken on numerous panels including the American Society for Clinical Oncology (ASCO), American Association for Cancer Research (AACR) and the Congressional Briefing with Breast Cancer Prevention Partners (BCPP). Through her life's work, Tiah is moving people from Awareness to Action. Today, We Discuss: 3:52 - 5:24 Tiah's diet growing up 13:46 - 18:56 Toxins in the products we use 21:05 - 21:48 Founding My Style Matters 26:46 - 29:12 Feeding vs fighting cancer Think Dirty App: https://thinkdirtyapp.com/ My Style Matters website: https://mystylematters.org/ My Style Matters Facebook: https://www.facebook.com/MyStyleMatters My Style Matters Instagram: https://www.instagram.com/mystylematters/?hl=en My Breast Years Ahead: https://www.facebook.com/groups/mybreastyearsahead/ Listen and Subscribe Facebook: https://www.facebook.com/pbnm.org/ Instagram: https://www.instagram.com/pbnmorg/ Youtube: https://www.youtube.com/channel/UCrHajqYAnc6b0syopySVkOg/ #nutrition #nutritiontips #nutritionfacts #nutritionstudent #educatorsmindset #educator #plantbased #plantbasedfood #plantbasedlife #plantbasedli

Dr. Diwakar Davar and Dr. Jason Luke, both of the University of Pittsburgh's Hillman Cancer Center, share the latest news on immunotherapy trials KEYNOTE-A10, LIBRETTO-001, and other key IO studies across tumor types featured at the 2022 ASCO Annual Meeting.  Transcript Dr. Diwakar Davar: Hello, and welcome to the ASCO Daily News Podcast. I am Dr. Diwakar Davar, and I'm an assistant professor of Medical Oncology in phase 1 therapeutics, at the University of Pittsburgh's Hillman Cancer Center, and the guest host of today's podcast. I'm delighted to welcome Dr. Jason Luke to this podcast. He's the director of the Cancer Immunotherapeutic Center at the Hillman Cancer Center, University of Pittsburgh, and a great colleague and friend.  Today we'll be discussing some key posters that highlight some advances in immunotherapy that will be featured and the 2022 ASCO Annual Meeting. You will find our collective disclosures in the show notes and the disclosures of all guests on the podcast are available on our transcripts at asco.org/podcasts.  So, Jason, thank you for coming on the podcast today.  Dr. Jason Luke: Well, thanks very much for the invitation. I always love doing these podcasts for ASCO, and never love anything more than hanging out with my friend Diwakar Davar.  Dr. Diwakar Davar: Well, thank you! Below are the abstracts we've selected. We will start with Abstract 2504. This is a phase 1 trial of the TIM-3 inhibitor cobolimab monotherapy, singly and in combination with the PD-1 inhibitors nivolumab or dostarlimab. Phase 1 data from the AMBER trial with the presenting author being Dr. Gerald Falchook. And this is a trial that initially started several years ago. And I know Jason, that you were involved with the inception of this agent, that TIM-3 inhibitor. So, walk us through, TIM-3. It's a third-generation checkpoint, we now have TIGIT LAG coming into the landscape. Definitely a first indication for LAG-3 melanoma with a positive trial, RELATIVITY 047. So, where are we with TIM-3? Why should we be excited about TIM in general, and this data in particular?  Dr. Jason Luke: It is quite exciting, especially building off the recent data that we saw for relatlimab or LAG-3 because it's becoming clearer that a number of these other immune checkpoints that we have been talking about for many years, actually really can be effective when used in the right setting.  So, this drug, this anti-TIM-3 antibody cobolimab monotherapy, as you mentioned, started out in a phase 1 clinical trial dating all the way back to I think about 2015. And that was at the time in immuno-oncology when everybody was so excited, [and] they thought everything was going to work immediately.  Subsequent to that, obviously, we've had some hurdles that we've had to come over. But we're coming back to some of these agents now, which are looking very exciting. So, just in the same way we think about blocking PD-1 or now blocking LAG-3 to reinvigorate T cells in the tumor microenvironment, there's a good chance and a high probability based on preclinical data that blocking TIM-3 could be just as effective as blocking LAG-3, so to say.  Now, one thing that I note in this abstract is really the safety finding and early PK analysis. And so, this is the important work we do early on to understand the drug. It's important to be aware that in a study like this, it's very hard to seek efficacy signals.  So, when you see this poster, really, you probably shouldn't be thinking, ‘Oh, this is a frontline phase 3 trial,' but rather that the efficacy is going to be a secondary consideration. Rather, what's quite important is looking at the properties of the drug and looking at the safety signals around that. And what we can see here is that TIM-3 appears to be quite safe when blocking it in conjunction with anti-PD-1 across several different tumor types. And that really sets the stage then to think about moving this into earlier lines of therapy across many different cancers.  And so, here we see advanced solid tumors but focused on lung cancer and melanoma and kind of the usual tumors we think about, and people can keep their eyes open because there are other posters of this molecule with PD-1 in some of the other sections outside of developmental therapeutics.  Now, one thing I would like to get your opinion on because your group has focused a lot on TIM-3, as I described it as this T cell centric mechanism to reinvigorate exhausted T cells. But it's possible that TIM-3 does other things as well. And I don't know if you want to comment on that or give any other feedback that you've had when thinking about this AMBER Trial.  Dr. Diwakar Davar: That was an excellent summary, Jason, of really what is a truncated 8-year track record of developing this agent all the way from 2015. But you bring up a very interesting point, which is: exactly what does this drug does in the non-T-cell compartment?  Some very interesting data from Brian Ruffell in a paper that was published about 3 years ago now suggested that TIM-3 was actually potentially a myeloid checkpoint, meaning that, in a tumor model in which Dr. Ruffell was studying this in the context of breast cancer, the drug primarily appeared to work on the effect of antigen-presenting cells and augment the presentation of antigen to T cells suggesting that it may be, in addition to being a chronicle T cell exhaustion marker, it may also be reinvigorating antigen-presenting cells. And the question of whether or not the role of TIM-3 on APCs as well as the role of TIM-3 on T cells, and which of these compartments are more important, and how these compartments segregate in any given cancer across many different lines of therapy will hopefully be something that we disengage, and understand a little bit better as we look at biomarkers of this drug across different settings.  And especially to that point, Jason, the biomarker question, you'll notice that very interestingly, that was a signal in which that drug had a certain response rate. Again, as you correctly point out, we cannot read too much into response rates in very small patient numbers. But very interestingly, there was a slightly higher response rate at the 300 milligrams, which is not the top dose level of the drug, and a slightly lower response rate at the ceiling dose of the drug that was tested, 900 milligrams, leading the investigators to conclude that the RP2D, was actually 300 milligrams every 3 weeks and not 900 milligrams.  What are your thoughts on dose in the context of immunotherapy (IO) drug development? And why might it be that 300 is the optimal dose as opposed to 900?  Dr. Jason Luke: That's a complicated question. I mean, when we think about checkpoint blockade, we classically think about it as only blocking on T cells. But to your point, if there are multiple mechanisms in play, sort of modulating other cell compartments actually may start to do different things at different doses that maybe weren't our primary intent as we went into the trial.  That's a little bit of hand waving, immunologic hand waving, but I think the data are the data and once we hit an effective dose level, there's really no need to really push the dose that much further. But that really emphasizes the importance of these kinds of early phase clinical trials.  So, I'm really looking forward to seeing this data. For disclosure, obviously, we have both been investigators on this trial. But we're very excited about the idea that there may be hope for a fourth checkpoint to come forward in the field beyond just PD-1 CTLA-4, and LAG-3, maybe now here with TIM-3.  Dr. Diwakar Davar: So, with that we'll go to the next abstract and that is Abstract 2516, “Phase I trial of adjuvant autogene cevumeran, an individualized mRNA neoantigen vaccine, for pancreatic ductal adenocarcinoma.”  So, this is an mRNA vaccine from our good friend, BioNTech. And that's been essentially evaluated in the context of highly lethal cancer, pancreatic ductal cancer, and specifically in the context of adjuvant vaccines, specifically in the setting of patients who had followed definitive pancreatic cancer surgery.  So, Jason, you know a lot of neoantigen vaccines, you've led some of these trials, really, the neoantigen vaccine is really the primary reason we are actually having an in-person meeting this year, because if not for this company and others like this, really this pandemic would not be behind us.  What are your thoughts on the role of neoantigen vaccines in cancer therapeutics, and also, particularly this particular trial in the data, the immunological data, and the clinical data regarding the development of neoantigen-specific T cells in this setting, and what this means for you?  Dr. Jason Luke: Right. So, the idea of targeting neoantigens as cancer immunotherapy was really all the rage a few years back, and it was thought based on preclinical animal models that this was just going to be the secret sauce, and this would be the new targeted therapy for immunotherapy. And it isn't to say that that's not true, but the first generation of neoantigen, peptide-based vaccines for the most part, unfortunately, just kind of didn't end up moving the needle the way we had hoped.  The question then was raised: is that because targeting neoantigens isn't reasonable, or is that because the setting where we were trying to do it in the refractory disease area was not the optimal way to leverage this?  And so, a couple of different companies and trials now are coming forward looking at targeting neoantigen in a minimal residual disease setting where the idea could be that immunologic responses that you could generate wouldn't be hampered by all the immunosuppression associated with the tumor microenvironment.  And so, here we have this molecule, which you eloquently pronounced, ‘autogene cevumeran.' It's an RNA-lipoplex neoantigen vaccine. So, it's not a peptide. It's more like the COVID-19 vaccines actually. And it's being given after surgery, followed by anti-PD-L1 followed by chemotherapy.  So, it's a complicated regimen, but it's very intriguing these early data, which do show that the patients who got the vaccine seemed to have better and longer-term outcomes. But then as you emphasize, really, I think probably what's at the heart of this that really makes it exciting is their ability to immune monitor the patients, meaning to look for antigen-specific immune cells from the peripheral blood in these patients to be able to identify those immune responses as being specific to cancer. Because this kind of a clinical trial, it's still signal seeking and proof of concept kind of trial.  In order to actually establish that a vaccine approach in a post-surgical setting would have efficacy, we need to do a large randomized trial. And so, this is not that yet. But I think these data really point in the direction that that could be a reasonable thing to try. And when you think about pancreatic cancer, where we've made no success with immunotherapy, really in a meaningful way in terms of checkpoint blockade, at least, that's pretty exciting actually to think about.  I would actually marry this dataset with another that we actually saw at the American Association for Cancer Research (AACR) meeting that also looked at neoantigen targeting and antigen-specific responses in colorectal cancer, again, and in a similar setting with the minimal residual disease setting.  And so, I think this highlights that we may need to start thinking about using immunotherapy in different ways than we had before. Obviously, everybody knows about using PD-1 blockade in lots of different cancer types that are really for metastatic disease, or maybe even for adjuvant now in melanoma a little bit. But maybe there's this space, which is the minimal residual disease setting where you might be able to detect by ctDNA after surgery, the patients are still positive. And maybe you could treat that before there's visible cancer, and maybe certain immunotherapies could be more valuable in that setting than others. And that's where I think maybe some of these mRNA technologies really might find their sweet spot.  So, coming back to this abstract, I think really, the emphasis point here is the novelty of generating patient-specific neoantigen vaccines, and then being able to track linearly over time the immune response against those vaccines.  I think with that kind of technology and being able to leverage that, I think we're really headed towards a real shift in the way we think about managing cancer in a post-surgical setting, again, thinking about MRD, or minimal residual disease, maybe in a way that our leukemia colleagues have been thinking it about for a long time.  Dr. Diwakar Davar: That's an excellent summary of a very, very complicated, both setting, and in this case, a therapeutic landscape. So, well said, well summarized, and we'll now pivot to Abstract 2514. So, this is ‘Efficacy and safety of NT-I7, long-acting interleukin-7, plus pembrolizumab in patients with advanced solid tumors: Results from the phase 2a study' [and] the presenting author is Dr. Aung Naing from [The University of Texas] MD Anderson [Cancer Center].  So, Jason, you know, with checkpoints, we've got so many thoughts about checkpoints, particularly given the rather unfortunate failure of BEMPEG in the context of melanoma.  So, we've got lots of interesting cytokines that we think of as important in the context of immuno-oncology 2, certainly 12, 15. You've been very involved with IO-15. We've got a lot of clinical trials studying IL-12. And now we've got one studying IL-7. So, tell us what do you think of this IL-7 targeting approach in the context of cytokine-based therapeutics?  Dr. Jason Luke: I think it's really important to emphasize on first principles, for those that are listening, who don't think about immunology all the time that not all cytokines are the same thing.  So, interleukin 2 that many people have heard of is very different actually than interferon. And that's very different from many of the other cytokines, the ILs, and everything, right?  So, IL-7 is a very potent cytokine that's associated with the expansion of immune responses, and that can drive interferon gamma-dependent effects. And you should hear whenever I say interferon-gamma is sort of a link through to PD-1 responsiveness. Because we think the mechanism that underpins anti-PD-1 effectiveness in patients really is interferon gamma biology.  So, IL-7 has been a molecule, it's been of a lot of interest but really was too toxic to try to deliver. But now we have novel drug delivery sorts of approaches that are being developed to try to bring the drug in, in a way that doesn't cause such systemic toxicity.  So, in this clinical trial, this NT-I7 molecule is given intramuscularly, every 6 weeks in conjunction with pembrolizumab, and very interestingly, in a small number of patients, but there were resist responses observed across a series of tumors that you really wouldn't expect should be responsive in any way to pembrolizumab alone. And so, we're talking about microsatellite stable colorectal cancer, pancreatic cancer, and some others as well.  And in conjunction with that, they were able to identify some of the biomarker effects we would think we would see with IL-7, such as expansion of peripheral immune compartments. And the toxicity profile was really consistent with what we've seen with fevers and chills, but manageable in a way that previous approaches really weren't.  So, I think this is really exciting because I think the idea here then is with this IL-7 approach, we might expand the kinds of cancers that we could go after, in conjunction with anti-PD-1 again, pancreas, colorectal cancer. I think that's really where the unmet need lies in oncology.  So, I really applaud these kinds of approaches and several of these cytokine approaches, and what we're going to talk about them, I think, have the potential to do that over the next couple of years.  Dr. Diwakar Davar: Excellent! Pivoting now to a different cytokine, but one that was alluded to before IL-12. So, Abstract 2518 is ‘Phase II evaluation of the combination of PDS0101, M9241, and bintrafusp alfa in patients with HPV 16+ malignancies,' and the presenting author here is Dr. Julius Strauss of the NCI Cancer Center and the Clinical Center of the National Cancer Institute at the National Institutes of Health.  So, what do you think, Jason, about the role of the HPV targeting vaccine, in this case, that was added to IL-12 immune-cytokine and bintrafusp alpha contextualizing the recent data that we have of bintra along with what is a very interesting result here?  Dr. Jason Luke: Yes, I think building on the last abstract where we talked about IL-7 as some novel biology now we move to IL-12, which again introduces other biology. So, interleukin-12 is a complicated cytokine, but one that's strongly associated with initial immune responses or immune priming, as well as enhancement of anti-tumor effects in the tumor microenvironment.  So, here we have sort of a 3-legged approach. So, the vaccination approach against HPV really can generate a strong immune response initially, and that can be supported with the IL-12. And then you come in with anti-PD-L1 and to whatever extent the TGF data is relevant here. And so, you have this cocktail where you're generating tumor-specific responses with a vaccine, you're supporting them with IL-12, and then blocking PD-L1.  And as we go back even a couple of abstracts we talked about, now we sort of have a cocktail right of approaches. And so, I think this is very exciting. It's unique in that, in these tumors, obviously, HPV is the driving force of cancer. So, developing a vaccine against that is fairly straightforward. But I really like this concept of bringing forward sort of a multi-dimensional immunotherapy approach. And we'll note they have previously presented data on this trial, I think last year at ASCO, actually. But what they see are pretty strong response rates, almost 30% range in PD-1 refractory tumors.  Again, that's our area of really high unmet need. It's hard to read through how useful a PD-1 naive treated patient here, although the response rates were high. But to me, it's really those patients who had progressed on PD-1 where they're getting these responses that tells me that this really could be something that's useful and potentially could be expanded beyond just say head neck cancer to any HPV relevant malignancy.  Dr. Diwakar Davar: Excellent! Now on to our last abstract. Abstract 2520, ‘Effect of intratumoral INT230-6 on tumor necrosis and promotion of a systemic immune response: Results from a multicenter phase 1/2 study of solid tumors with and without pembrolizumab (PEM) [Intensity IT-01; Merck KEYNOTE-A10].' The first author is Dr. Jacob Thomas.  Jason, we've seen a lot of interesting intratumoral therapies. You and I have both done a lot of studies in looking at intratumoral agents from toll-like receptor agonists, TLR-9, TLR 7-8, and more recently, oncolytic viruses.  So, contextualizing IT230-6 in the spectrum of intratumoral therapies, how do you feel about this drug, which is actually a very interesting novel drug. It's not just a TLR agonist, or for that matter, an OV, very interestingly, it's an intratumoral therapy that has actually got chemotherapy in it. So, how do you feel about this drug? How do you feel about the responses that we've seen? And particularly how do you feel about the setting in neoadjuvant breast cancer?  Dr. Jason Luke: Yeah. I would pick up where you said that this drug INT230-6 is just a really interesting concoction. So, it's cisplatin mixed with vinblastine, in a specific amphiphilic molecule that allows it to diffuse in through the cancer.  And so, if you had said that to me a few years ago, I would have looked at you and been like, ‘What are you talking about?' But I think the data that's been emerging for this is just really interesting because something about this chemotherapy cocktail actually drives immune responses. And really what the focus of this abstract is on is showing that you get an influx of CD foreign CDTa cells into the tumor microenvironment that's associated with a therapeutic benefit.  I think that's just really, really interesting to think about. It sort of makes one wonder when we're doing these intratumoral injections, how much of it is just the injection, and how much of it is the therapeutic agent, but I think it's a really novel therapy, and one that appears to be very well tolerated as well. And that's also the exciting part. When you hear cisplatin and vinblastine, you think, ‘Oh, well, that's not going to work.'  But apparently, it stays right in the tumor and generates these immune effects. I think it's very exciting. I think their approach here—going after what we usually call cold tumors, ones that don't respond to immunotherapy, you mentioned breast cancer—I think it's really interesting. I'm really looking forward to seeing the actual data from this abstract because, on first pass, it wouldn't have been what I thought about in terms of driving immune responses, but maybe it just goes to show that there's a lot more to understand there about immunogenic cell death and some of these other concepts that we bandy about. But I think this will be one of the most interesting abstracts actually to see the data for once it's available.  Dr. Diwakar Davar: Great! Taking a slight pivot from that. You've been involved in the development of novel response endpoints. One of the issues that we have with intratumoral therapies is that you're measuring a lesion that you inject, so now you inject something and it gets a little bigger. Is it getting bigger because it's growing? Is it getting bigger because the drug is working? We don't know. We have now itRECIST, which you have been working on.  What's very interesting is that whether you look at itRECIST, or RECIST, irRECIST, or imRECIST, when you have the monopoly of different response endpoints we have to deal with these days, these patients have monotherapy responses in non-injected tumors. How do you feel about that as a drug developer and somebody who's giving patients drugs like that? What is your impression of having shrinkage in the non-injected tumor?  Dr. Jason Luke: I think it's really exciting about this concept of the abscopal effect that we've bandied about for years. Despite being an investigator in this space, I'm really excited to actually see the data and to understand what these out of field responses are. If it's really true that this is robust, I mean, it could potentially be like a game-changer kind of thing. But I'll reserve judgment until I see the actual scans of the tumors that actually shrank that weren't injected.  Dr. Diwakar Davar: Fantastic insights, Jason. So, thank you for taking the time to join us on this podcast and to highlight these extraordinarily important advances in immunotherapy.  Dr. Jason Luke: I appreciate the opportunity to participate today.  Dr. Diwakar Davar: So, thank you, and thank you to our listeners for your time today, you will find the links to the abstracts that we discussed today in the transcript of the episode.  Finally, if you're enjoying the content on the ASCO Daily News podcast, please take a moment to rate review and subscribe wherever you get your podcasts.  So, thank you, Jason. And thank you to the team for putting this together.      Disclosures:   Dr. Diwakar Davar:   Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences  Consulting or Advisory Role: Instil Bio, Shionogi (Immediate Family Member), Vedanta Biosciences  Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, Zucero Therapeutics (Inst), GSK, Merck, Arcus Biosciences  Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231, and Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy  Dr. Jason Luke:  Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX   Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, Stipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences , Hotspot Therapeutics, SERVIER , STINGthera, Synthekine  Research Funding (Inst): Merck, Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma, EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure  Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)  Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio  Disclaimer:   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. 

This year's American Association for Cancer Research (AACR) congress took place in New Orleans, LA, from 8-13 April 2022, and... The post Updates in GI cancers from AACR 2022 appeared first on VJOncology.

This year's American Association for Cancer Research (AACR) congress took place in New Orleans, LA, from 8-13 April 2022, and... The post Updates in GI cancers from AACR 2022 appeared first on VJOncology.

In Episode 17, Season 4 of the Amplifying Scientific Innovation® Video Podcast, Dr. Sophia Ononye-Onyia, Founder and CEO of The Sophia Consulting Firm, interviewed Dr. Mostafa Analoui, Executive Director of Venture Development and Technology Incubation Program (TIP) at UConn. By coupling UConn's world-class research resources, facilities, and business support services to a network of experienced investors and entrepreneurs, UConn's TIP helps launch startups ready to transform their respective markets. This episode showcases Dr. Analoui's unique perspectives on science advocacy, health equity and influential leadership. Episode 17 also recognizes the annual meeting of the American Association for Cancer Research (AACR), the first and largest cancer research organization dedicated to accelerating the conquest of cancer. For full transcript, please visit: https://sophiaconsultingfirm.com/blogs-%2B-articles/f/amplifying-scientific-innovation%C2%AE-dr-mostafa-analoui-uconn

Cynthia lives in Lawrenceville, NJ with her husband John. She attended Rutgers University graduating with degrees in Psychology and Education. Upon graduation she secured her first teaching position and immediately fell in love with her chosen profession. Cynthia continued teaching for 28 years. Cynthia, a myeloma survivor, was forced to retire from her beloved teaching career when a stem cell transplant failed to put her cancer into remission. Now retire, she is using her passion for education to teach a new group of "students" - myeloma patients and their caregivers. Using social media to educate is her passion. Cynthia educates and advocates by tweeting @MyelomaTeacher and sharing myeloma resources, educational opportunities, and clinical trial information on her MyelomaTeacher Facebook page. She is the curriculum director of the Myeloma Crowd's HealthTree University for Myeloma- a free online myeloma education course. https://healthtree.org/myeloma/university Ms. Chmielewski is also a regular patient panelist on CureTalks Podcast. Cynthia sits on the advisory boards of the Patient Empowerment Network, the Myeloma Crowd Research Initiative, and several pharmaceutical companies. Cynthia was an invited panelist and presented posters on using social media in hematology at the annual meetings of the American Society of Hematology (ASH), the American Association for Cancer Research (AACR) and the European Bone Marrow Transplant (EBMT). Additionally, Cynthia is also a member of the Patient Engagement team at Patient Power-A Remedy Health Company. Ms. Chmielewski enjoys serving as a voting member on the IRB at the University of Pennsylvania, a peer reviewer for the National Cancer Institute's (NCI) Division of Extramural Affairs and Department of Defense's CMCRP grant programs. Ms. Chmielewski is a patient advocate on the myeloma steering committees of the NCI and the Academic and Cancer Research United (ACCRU.) More recently Cynthia was asked to serve as a patient advocate on the Mayo Clinic's Myeloma SPORE. She is also the patient advocate on several research grants. Cynthia serves as a community member on the Rutgers-Cancer Institute of NJ's Community Cancer Action Board and Mt. Sinai's Cancer Care Accelerator Group.

On this week's episode FirstWord Pharma PLUS editors Virginia Li, Michael Flanagan and Simon King look ahead to the annual meeting of the American Association of Cancer Research (AACR) which is taking place this weekend in New Orleans.

“You know, after the drug gets approved, it's a feather in your cap. You have been part of an NDA, that's great. Your value goes up. But after that, what do you do?” -Neil Sankar MD, MPH In this episode, DocWorking Founder and CEO, Dr. Jen Barna welcomes Dr. Neil Sankar. Dr. Sankar is President and Chief Medical Officer of SwanBio, LLC, a business development consultancy firm that facilitates the translation of scientific discoveries into cancer therapeutics. Dr. Sankar has over 16 years of experience in life sciences clinical development, pipeline strategy, clinical safety, and pharmacovigilance. Dr. Sankar shares his wealth of experience in the pharmaceutical industry with the DocWorking audience. He tells us about his journey, his tips for those wanting to get into pharmaceuticals and how he finds time to relax. If you are thinking about getting into the pharmaceutical industry, you will find this episode extremely helpful!   Neil Sankar received his MD degree from Bangalore University and internal medicine residency from University of West indies, Kingston, Jamaica and trained in the UK and the Caribbeans. He holds a postgraduate degree in public health from Queensland University in Australia.   Dr. Sankar got his training in clinical research and tumor biology from NCI Bethesda Maryland and since has held Clinical Development positions within leading Biotech/Pharma including Genentech, Medimmune, Pharmacyclics, FiveprimeTherapeutics, Portola, Loxo Oncology, Otsuka Pharmaceuticals, Elevar Therapeutics, Boston Biomedical, Effector Therapeutics and  Rhizen Pharmaceuticals to name a few.   Dr. Sankar is President and Chief Medical Officer of SwanBio, LLC, a business development consultancy firm that facilitates the translation of scientific discoveries into cancer therapeutics. Dr. Sankar has over 16 years of experience in life sciences clinical development, pipeline strategy, clinical safety, and pharmacovigilance. He has extensive experience in the application of US Food and Drug Administration regulations and the Good Clinical Practice guidelines set forth by the International Council on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. He has acted as Medical lead in numerous phase I, II and III clinical trials in the therapeutic area of oncology ranging from solid tumors, connective tissue tumors to hematological malignancies including, CLL/SLL, B cell lymphomas, T cell Lymphomas, Acute Myeloid Leukemia and Hodgkins Lymphoma. He is an expert in providing global clinical development and regulatory strategies for therapeutic drugs and was instrumental in filing the New Drug Applications for the antibody-drug conjugate in Metastatic Breast cancer and the Bruton tyrosine kinase inhibitor in Mantle cell Lymphoma. Dr. Sankar has extensive experience in designing and deploying data capture tools that evaluate the efficacy and safety of clinical trials. He also has extensive experience as a member of drug safety committees and advisory boards of few companies including Leukemia Therapeutics and iNDX Technology. Dr Sankar has led or has been part of FDA/Regulatory Authority discussions for various companies pursuing IND and NDA applications including Pre-IND and Pre-NDA F2F meetings.   Dr. Sankar is an active member of the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), the European Hematology Association (EHA , Drug information Association (DIA) , European Society of Clinical Oncology (ESMO), American Association for Cancer Research (AACR), Enterprising Pharmaceutical Professionals from the Indian Sub-Continent (EPPIC GLOBAL), Connective Tissue Oncology Society (CTOS), IACA and TiE Silicon Valley. Find full transcripts of DocWorking: The Whole Physician Podcast episodes on the DocWorking Blog  DocWorking empowers physicians and entire health care teams to get on the path to achieving their dreams, both in and outside of work, with programs designed to help you maximize life with minimal time.   Are you a physician who would like to tell your story? Please email Amanda, our producer, at Amanda@docworking.com to be considered.   And if you like our podcast and would like to subscribe and leave us a 5 star review, we would be extremely grateful!   We're everywhere you like to get your podcasts! Apple iTunes, Spotify, iHeart Radio, Google, Pandora, Stitcher, PlayerFM, ListenNotes, Amazon, YouTube, Podbean   You can also find us on Instagram, Facebook, LinkedIn and Twitter.    Some links in our blogs and show notes are affiliate links, and purchases made via those links may result in payments to DocWorking. These help toward our production costs. Thank you for supporting DocWorking: The Whole Physician Podcast!   Occasionally, we discuss financial and legal topics. We are not financial or legal professionals. Please consult a licensed professional for financial or legal advice regarding your specific situation.   Podcast produced by: Amanda Taran

BUFFALO, NY-March 22, 2022 – Impact Journals publishes scholarly journals in biomedical sciences with a focus on all areas of cancer and aging research. Impact Journals will be participating as an exhibitor at the American Association for Cancer Research (AACR) 2022 annual meeting from April 8-13, 2022, in New Orleans, Louisiana. This year, the AACR conference is entitled, “Decoding Cancer Complexity | Integrating Science | Transforming Patient Outcomes.” Oncotarget and Aging (Aging-US) are Impact Journals' two most prominent journals. Oncotarget is a peer-reviewed, open-access journal dedicated to publishing high-quality, primarily oncology-focused research—in a continuous format within ongoing yearly volumes. Aging is a twice-monthly, traditional, peer-reviewed, open-access journal covering all areas of research on aging, including age-related diseases such as cancer and COVID-19. Visit booth No. 2012 at the 2022 AACR annual meeting from April 8-13, 2022, to connect with members of the Impact Journals team. To learn more about Impact Journals, visit www.ImpactJournals.com. For media requests, please contact media@impactjournals.com. Follow us on social media: Oncotarget Twitter – https://twitter.com/Oncotarget Oncotarget Facebook – https://www.facebook.com/Oncotarget Oncotarget YouTube – www.youtube.com/c/OncotargetYouTube Aging YouTube – https://www.youtube.com/agingus Aging LinkedIn – https://www.linkedin.com/company/aging Aging SoundCloud – https://soundcloud.com/aging-us Impact Journals LLC 6666 E.Quaker St. Ste. 1 Orchard Park, NY 14127

The man, the myth, the legend Joe Bullock makes his 3rd appearance on the Man Up to Cancer Podcast to talk about: His recent visit to Washington D.C. for the Call on Congress event organized by https://fightcolorectalcancer.org/ (Fight Colorectal Cancer). They are on a mission to make our legislators recognize colorectal cancer as a national priority, and to urge the National Cancer Institute to develop a strategic action plan for colorectal cancer. The new 'Chemo Backpack' program that Man Up to Cancer is launching this month, with support from Natera and the American Association for Cancer Research (AACR). 'Captain' Jackson Forssberg and the early development of http://colontown.org/junior-support/ (COLONTOWN Junior). Joe is the program manager for this group that connects families with children who have been diagnosed with colorectal cancer. We should have 4 episodes with Joe, but one of the tapes from 2020 mysteriously disappeared. We think it will show up in a time capsule in a few hundred years. SPONSOR SHOUT-OUT! Today's episode is brought to you exclusively by the good folks at Blue Note Therapeutics. Blue Note creates prescription digital therapy apps to help patients address the common yet overlooked side effects of cancer, like stress, anxiety, and depression. Check out their new, fully remote clinical trial at https://bluenotetherapeutics.com/trials (bluenotetherapeutics.com/trials).

Chinese immuno-oncology companies are changing how they interact with FDA as they seek approval of PD-1 programs. On this episode of BioCentury This Week, BioCentury's editors discuss takeaways from a survey of CEOs and R&D heads developing PD-1 or PD-L1 inhibitors about what's next for their programs. The team also previews translational data expected at next month's meeting of the American Association for Cancer Research (AACR) and legislation making its way through Congress as the House Energy and Commerce Committee's health subcommittee prepares to gather. This week's podcast is sponsored by life sciences investment firm Jeito Capital. 

Mel Mann is the World's Longest Living Gleevec (Imatinib) & TKI & Kinase Inhibitor Survivor, 27 Year Terminal Leukemia (CML) Survivor; US Army Retired, Educator, Patient Advocate & Consultant. He Published and appeared in articles such as USA Today, Coping With Cancer Magazine, American Association for Cancer Research (AACR), Cancer Today Magazine etc. He also appeared on numerous television & radio shows as a patient advocate and made a nationwide television commercial for the American Cancer Society (ACS). He has participated on panels such as The Atlantic's People vs Cancer series, Hematology Oncology Pharmacy Association (HOPA), WCG, Patient Power etc. Mel Mann actively collaborates on health equity and ethnic diversity issues with groups such as the American Cancer Society's Cancer Action Network (ACSCAN), Society of Integrative Oncology (SIO) etc. He has participated in numerous nationwide bone marrow drives, including the World's Largest, with 10,675 people joining the marrow registry at a single drive and collaborated in marrow donor recruitment for Be The Match, DKMS Marrow, and the Bill Young Marrow Donor organizations. He is the past National Community Outreach Coordinator of Leukemia & Lymphoma Society's (LLS) Myeloma Link program. He has been a Guest Speaker for Cepheid, Churches, Community Organizations, Leukemia & Lymphoma Society, Cancer Support Groups and the US Army. For being a marrow donor, please visit: http://join.bethematch.org/MelMann.

Il vaccino anti Covid è efficace nei pazienti oncologici, ma per ottenere un’adeguata protezione sono indispensabili due dosi. A dimostrarlo uno studio italiano pubblicato su “Clinical Cancer Research”, la rivista ufficiale dell’American Association for Cancer Research (AACR), che commentiamo a Obiettivo Salute con il prof. Francesco Cognetti, Professore di Oncologia Medica Sapienza Università di Roma e Direttore Oncologia Medica Regina Elena di Roma, che ha coordinato la ricerca Ed è sempre italiana una ricerca che ha trovato una molecola in grado di aiutare la diagnosi di fragilità nell’anziano. La ricerca pubblicata sull’autorevole rivista Journal of Gerontology, ha messo in luce il ruolo chiave dell’alimentazione sottolineando l’importanza di un consumo adeguato di frutta e verdura. Ci spiega il perché Laura Brunelli, Coordinatrice della ricerca e Ricercatrice dell’Unità di Bioindicatori Proteici e Metabolici dell’Istituto Mario Negri

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive its collaborators have presented positive preclinical data for the combination of REQORSA, the company's proprietary TUSC2 immunogene therapy, in combination with chemotherapy and immunotherapies for the treatment of non-small cell lung cancer (NSCLC). Varner says the data were presented in two presentations at the 2021 American Association of Cancer Research (AACR) annual meeting. The positive data is helpful for Genprex's plan to launch a pair of upcoming clinical trials.

Aging is indexed by PubMed/Medline abbreviated as “Aging (Albany NY)”, PubMed Central, ISI/Web of Science: Science Citation Index Expanded (abbreviated as Aging‑US and listed in the Cell Biology category; since June 2017 it has also been listed in the Geriatrics & Gerontology category), and Scopus /Rank Q1 (abbreviated as Aging). Every year, the American Association for Cancer Research (AACR) organizes a conference program that covers the latest discoveries in cancer research. Topics include population science and prevention, cancer biology, translational and clinical studies, survivorship, and advocacy. This conference aims to highlight work from the best minds in research and medicine from institutions all over the world. The journal Aging, by Impact Journals, will be participating at the AACR Annual Meeting this year. Visit Aging website: https://www.aging-us.com/ Impact Journals is an open-access publisher of rigorously peer-reviewed scientific literature, and owns several medical research journals, including Aging. Aging was launched by Impact Journals in 2009 with the goal of spotlighting high-impact papers, authored by scientists who study the process of aging and age-related diseases—including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Visit Impact Journals website: https://www.impactjournals.com/ Aging has published outstanding papers and reviews by highly-cited authors and award winners, including Andrew V. Schally (Nobel Laureate), Shinya Yamanaka (Nobel Laureate), Lawrence Donehower, Toren Finkel, Stephen Helfand, Gerald Shadel, Andre Nussenzweig, Maurice Burg, Karen Vousden, Leonard Guarente, and Dale Bredesen. Importantly, the Aging Editorial Board also comprises numerous prestigious award winners, including Nobel Laureate Elizabeth H. Blackburn, and many other distinguished scientists, including Cynthia Kenyon, Judith Campisi, Leonard Guarente, Michael Hall, Mikhail Blagosklonny, Vera Gorbunova, David Sinclair, Jan Vijg, and Thomas Rando. The journal has recently concluded its 12th year of publishing and has become Impact Journals' featured journal. Learn more about Aging and Impact Journals at the virtual 2021 AACR conference on April 10-15 and May 17-21, 2021. Registration will be open through the beginning of the event. More About Aging Launched in 2009, Aging publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways. Please visit our website at http://www.Aging-US.com​ or connect with us on: SoundCloud - https://soundcloud.com/aging-us Twitter - https://twitter.com/AgingJrnl Facebook - https://www.facebook.com/AgingUS/ YouTube - https://www.youtube.com/agingus LinkedIn - https://www.linkedin.com/company/aging Aging is published by Impact Journals, LLC please visit http://www.ImpactJournals.com​ or connect with @ImpactJrnls Media Contact 18009220957 MEDIA@IMPACTJOURNALS.COM

The American Association for Cancer Research (AACR) organizes an annual meeting program covering some of the most recent discoveries in cancer research. The conference aims to highlight work from the best minds in research and medicine from institutions all over the world. Oncotarget, exhibited by its publisher Impact Journals, will be participating virtually at the AACR Annual Meeting this year. Visit the Oncotarget website: www.oncotarget.com Visit the Impact Journals website: www.impactjournals.com As of June 2020, Scopus released their latest 2019 Journal Rankings on Oncology. Oncotarget is among their highest rated (Q1) journals and ranked number one in total citations in oncology. The journal has published outstanding papers and reviews by authors including Bert Vogelstein, Peter K. Vogt, Pier Paolo Pandolfi, Arnold J. Levine, Brian Druker, and Carol Prives. Founding Oncotarget Editorial Board members include Nobel Laureates Andrew V. Schally and Gregg L. Semenza; Lasker Award recipients Alexander Varshavsky, Brian J. Druker, and Gregg L. Semenza; and 16 members of the US National Academy of Sciences. Oncotarget is indexed and archived in PubMed, PubMed Central, Scopus, EMBASE, and META (Chan Zuckerberg Initiative). The 2021 AACR conference, a two-week online event, will take place from April 10-15 and May 17-21, 2021. Topics include population science and prevention, cancer biology, translational and clinical studies, survivorship, and advocacy. In 2019, Oncotarget participated in the AACR Annual Meeting at the Georgia World Congress Center in Atlanta, Georgia, USA, and "AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics," at the Hynes Convention Center in Boston, Massachusetts, USA. The total registration count from the 2019 AACR Annual Meeting was over 21,000—nearly 16,000 of which were scientific attendees from all over the world. Follow the Oncotarget Twitter account (@Oncotarget) for live updates about the conference using the #AACR21 hashtag. About Oncotarget: Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit www.oncotarget.com or follow us: SoundCloud - @oncotarget Facebook - www.facebook.com/Oncotarget/ Twitter - twitter.com/oncotarget LinkedIn - www.linkedin.com/company/oncotarget Instagram - www.instagram.com/oncotargetjrnl/ YouTube - www.youtube.com/OncotargetYouTube Pinterest - www.pinterest.com/oncotarget/ Reddit - www.reddit.com/user/Oncotarget/ Oncotarget is published by Impact Journals, LLC please visit www.ImpactJournals.com or connect with @ImpactJrnls Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Welcome to a special Holiday 2020 Episode! Episode 104: A special case study on how Valuegraphics (https://valuegraphics.com/) can help an organization like the American Association for Cancer Research (https://www.aacr.org/) to engage with their high-value gift donors. CHECK OUT the AACR's NEW game here: http://neoantigen.gg/!!!  (Proceeds from the game will benefit cancer research.) This is a very special episode of the Self Made Strategies Podcast.  We brought back two former guests (Mitch Stoller, Chief Philanthropic Officer of the American Association for Cancer Research, who previously appeared on Episode 039 of the Self Made Strategies Podcast; and, David Allison, Founder of Valuegraphics, who previously appeared on Episode 089 of the Self Made Strategies Podcast) to do a case study discussion to help raise awareness for the American Association for Cancer Research's initiatives to combat cancer.  Cancer started this fight, but the AACR WILL END IT (especially with support from great listeners like YOU!)! Here are some quick Cancer facts (courtesy of https://playersvscancer.org/neoantigen/): 1 in 3 people will develop cancer in their lifetime. Cancer cases are expected to increase by 45% by 2030 40% of all cancers are preventable Let's do our part by joining the AACR in its fight against cancer. Our podcast is also available on YouTube (please subscribe): https://youtube.com/channel/UCOG-mybCfvYWhoXo4vPoB5g More about Mitch: Mitch Stoller is the Chief Philanthropic Officer of the AACR Foundation and Vice President of Development. The American Association for Cancer Research (AACR) is the first and largest cancer organization in the world, with 44,000 members in 120 countries. In his role, Stoller is responsible for leading the Foundation team to increase organizational brand awareness and to secure critical funds to support cancer research through strategic partnerships with corporations, foundations and individual giving initiatives. With more than 30 years of experience as a non-profit executive, Stoller’s leadership has been instrumental to many high-profile organizations, including the Lance Armstrong Foundation (LiveSTRONG), the Christopher Reeve Paralysis Foundation, and the Sudden Infant Death Syndrome Alliance. He was responsible for and implemented the iconic LiveStrong yellow wristband campaign, which raised over $75 million, and launched a fundraising paradigm. He joined the AACR Foundation in 2013. More about David: David Allison is a human behavior expert and the pioneer of Values Thinking. His research and advisory services are used in industries as wide-ranging as sportswear, school supplies, luxury goods and hedge funds. He works with global humanitarian foundations like the Environmental Defense Fund and the United Nations.   He is the founder of the Valuegraphics Database (check it out here: valuegraphics.com), the first statistically accurate global measurement of what everyone on earth cares about, and his research has led him to become an outspoken advocate for the eradication of demographic stereotypes.  He speaks internationally, and his most recent book "We Are All the Same Age Now" was an international marketing #1 best-seller, named one of the top ten Leadership Books of the year by INC magazine, and called "a genuinely original contribution to marketing literature" by Kirkus Reviews.  You can check out or purchase "We Are All the Same Age Now" here: https://read.amazon.com/kp/embed?asin=B07GTBQB2J&preview=newtab&linkCode=kpe&ref_=cm_sw_r_kb_dp_5DAwFbQTTZVB5&tag=softstix-20 On this episode you will hear Mitch and David discuss: How the AACR is using Players vs Cancer to raise critical funds and awareness, in collaboration with the gaming community, to benefit the AACR’s mission to prevent and cure all types of cancer Why values are more important than demographics and psychographics How to use valuegraphic data to determine what really matte...

Today is World Cancer Day! My mom's response to this was "thank you" and my boyfriend's response was: "congratulations." Yup! That's where we're at folks. Today I am reading a few facts out loud via the The American Association for Cancer Research (AACR) and from EverydayHealth.com, because staying in the know can only help. -- Please consider leaving a review on Apple Podcasts, it is most appreciated! -- This episode is brought to you by BALLSY. Use Code Laugh20 for 20% off your "I Am Nuts About You" gift set that will arrive by V-Day. Boom! -- Say hi! DyingOfLaughterPodcast@gmail.com @_ChelsWhoElse_ | @dyingoflaughter_podcast

Mitch Stoller is the Chief Philanthropic Officer of the AACR Foundation and Vice President of Development. The American Association for Cancer Research (AACR) is the first and largest cancer organization in the world, with 44,000 members in 120 countries. In his role, Stoller is responsible for leading the Foundation team to increase organizational brand awareness and to secure critical funds to support cancer research through strategic partnerships with corporations, foundations and individual giving initiatives. With more than 30 years of experience as a non-profit executive, Stoller’s leadership has been instrumental to many high-profile organizations, including the Lance Armstrong Foundation (LiveSTRONG), the Christopher Reeve Paralysis Foundation, and the Sudden Infant Death Syndrome Alliance. He was responsible for and implemented the iconic LiveStrong yellow wristband campaign, which raised over $75 million, and launched a fundraising paradigm. He joined the AACR Foundation in 2013. On today’s episode we will:• Get to know Mitch and hear more about the AACR• Talk about the AACR’s upcoming events• ˆProgress and Promise Against Cancer with NBC and Telemundo: on the air on 11/19/19 • Runners for Research, Philadelphia Marathon: happening on 11/23/19 – 11/24/19• Revolutions for Research: happening on 12/07/19• Discuss how Mitch is innovating a large organization and helping move the AACR in a new direction• Then we will dive into the organizational strategies Mitch uses to get buy-in from industry stakeholdersOn this episode of the Self Made Strategies Podcast, you will learn about: • The LiveSTRONG Yellow Wristband Campaign, as well as Mitch’s role in that campaign, and how that led to where Mitch is now with the AACR Foundation.• The development strategies Mitch is implementing to help grow and innovate the AACR• How to bring innovation to large organizations• Whether you should focus mainly on marketing to a new audience, or to find innovative ways to approach your existing audience• The pitfalls and hurdles you might face, while trying to grow a large organization’s outreach• The upcoming events the AACR is planning, and the new campaigns they are preparing for 2020• As a bonus, you will hear about what Mitch is planning for 2020, to bring innovation to the AACR• And so much more!After you’ve listened to the episode, make sure you visit the AACR (at https://www.aacrfoundation.org/) to donate, get more information, or join one of their upcoming events. You can also follow the AACR Foundation on Facebook (https://www.facebook.com/AACRFoundation), Twitter (https://twitter.com/AACRFoundation), or Instagram (https://www.instagram.com/aacr_foundation/). As always, you can always go to www.SelfMadeStrategies.com for more information about our show, exclusive content and to contact the Self Made Strategies hosts.You can also connect with us on: • https://www.facebook.com/selfmadestrategies/ •• https://twitter.com/SelfMadeStratGs •• https://www.instagram.com/selfmadestrategies/ •• https://www.linkedin.com/company/self-made-strategies/ •

Adam Hayden is a philosopher of science, a champion of the humanities in medical education, an advocate for palliative care, and a person living with brain cancer (glioblastoma). He serves on multiple national advisory councils focused on patient engagement and advocacy, he is a member of the American Association for Cancer Research (AACR) scientist-survivor program and he co-moderates a monthly social media chat and a virtual support group for the brain tumor community.Adam Hayden will be a featured speaker at this year's EndWell Conference in San Francisco. If you are interested in attending EndWell click here. See acast.com/privacy for privacy and opt-out information.

Howard Brown was first diagnosed with cancer - Non-Hodgkins Lymphoma - at the age of 24. When he turned 50, a routine colonoscopy revealed stage 3 colon cancer. During our conversation we discussed: The numerous treatments, including HIPEC, and clinical trials he's been through. His experience as an an attendee of the 2019 American Association of Cancer Research (AACR) conference. How his twin sister saved his life from stage 4 Non-Hodgkins Lymphoma. The possible link between childhood and young adult cancers to adult cancers. His experience being treated with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) What his cancer experience has taught him about himself. How exercise has helped him physically and emotionally. His thoughts, and mine, on healthy eating. Links Mentioned In the Show Stacy Hurt - https://stacyhurt.net/ AACR - https://www.aacr.org/Pages/Home.aspx Gentle Yoga With Jean DiCarlo Wagner - https://Wehavecancershow.com/019 Colontown - https://colontown.org/colontown-intake-form/ Belong.Life App - https://belong.life/ WE Have Cancer Links Subscribe to the show - https://pod.link/wehavecancer Follow WE Have Cancer on Social Media Like our Facebook page - https://www.facebook.com/wehavecancershow/ Join our private Facebook group - https://www.facebook.com/groups/wehavecancershow/ Follow us on Twitter - https://twitter.com/wehavecancerpod Follow us on Instagram - https://instagram.com/wehavecancerpod Follow us on LinkedIn - https://linkedin.com/company/wehavecancer Know someone touched by cancer who has an inspiring story? Nominate a guest to appear on the podcast - https://wehavecancershow.com/guest Email Lee Lee@wehavecancershow.com

Dr. Shaheenah Dawood is the Head of Medical Oncology and the Head of the Breast Cancer Program at Dubai Hospital in the United Arab Emirates. Dr. Dawood completed her M.B.B.Ch at Dubai Medical College in 1998 and a Master of Public Health degree at the Harvard School of Public Health, Boston, USA in 2008. Her postgraduate medical training programs include a Fellowship at McGill University in Canada in 2006, and the Susan Komen Breast Cancer Fellowship at the University of Texas M.D. Anderson Cancer Center in 2007. Dr. Dawood is a member of various professional organizations, including the American Society of Clinical Oncology (ASCO), the American Association of Cancer Research (AACR), the Canadian Association of Medical Oncologists, the Emirates Medical Association, and the Inflammatory Breast Cancer Research Group. She is also the co-director of the Middle East Research Network. If you enjoyed this podcast, make sure to subscribe for more weekly education content from ASCO University. We truly value your feedback and suggestions, so please take a minute to leave a review. If you are an oncology professional and interested in contributing to the ASCO University Weekly Podcast, email ascou@asco.org for more information. TRANSCRIPT [MUSIC PLAYING] Welcome to the self-evaluation episode of the ASCO University Weekly Podcast. My name is Shaheena Dawood, and I am a consulting medical oncologist and lead of the Oncology Research program at the Comprehensive Cancer Center at the Mediclinic City Hospital in Dubai, United Arab Emirates. Today, we feature a self-evaluation question looking at the predictive and prognostic role of pathological complete response attained in the treatment of breast cancer. Let us begin by reading the question stem. Here, we have a 55-year-old woman who presents with a 4 centimeter right breast mass and palpable right axillary lymph nodes. A needle biopsy of the breast mass and a lymph node are both positive for infiltrating ductal carcinoma negative for hormone receptors and negative for HER2/neu expression. The patient is interested in breast-conserving therapy, and she is referred to you for consideration of neoadjuvant chemotherapy. Which of the following do you tell her? Your choices are, A-- patients having a complete response to neoadjuvant chemotherapy have lower local and regional recurrence rates, B-- mastectomy will be required regardless of clinical response to chemotherapy, C-- chemotherapy will be administered before and after surgery, or D-- randomized trials have shown that radiotherapy is not necessary following surgery and chemotherapy if she has a complete response. At this point, please feel free to pause the recording before we discuss the correct answer. [MUSIC PLAYING] The correct answer to this question is A. Pathological complete response in the breast and lymph nodes is associated with lower local and regional recurrence rates. A combined analysis of the NSABP B18 and B27, two large trials that evaluated the role of neoadjuvant chemotherapy, revealed that the rate of local regional recurrence decreased amongst patients who initially presented with positive lymph nodes prior to neoadjuvant chemotherapy, and who become pathologically node negative after neoadjuvant chemotherapy, especially if they also achieved a pathological complete response in the breast. Briefly, the other choices presented in this question do not represent the most appropriate answer for the following reasons. The decision regarding type of surgery in the form of mastectomy versus breast-conserving surgery is dependent on multiple factors. One of the early established benefits of neoadjuvant therapy is that it increases the probability of breast-conserving surgery, making more women candidates for lumpectomy and breast radiotherapy, who otherwise would have been treated with mastectomy. Studies have shown that chemotherapy before surgery in the neoadjuvant setting versus chemotherapy after surgery in the adjuvant setting is associated with similar outcomes. And finally, attaining a pathological complete response currently does not preclude the need for adjuvant radiation therapy, the decision of which would be made on clinical stage of disease at presentation. The NSABP51 RTOG phase III trial is ongoing to evaluate the role of regional radiotherapy in women presenting with clinical N1 axillary node disease before neoadjuvant chemotherapy, and who become pathologically node negative at the time of surgery. Thank you for listening to this week's episode of the ASCO University Weekly Podcast. For more information on the treatment of breast cancer, including opportunities for self-evaluation and board review, please visit the comprehensive e-learning center at university.asco.org. [MUSIC PLAYING] The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care, and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Konuşmacımızın Özgeçmişi: Dr. Fatih İnci, Stanford Üniversitesi, Tıp Fakültesi'ne bağlı Kanser Erken Teşhisi Merkezi'nde akademik çalışmalarına devam etmektedir. Kendisi biyomühendislik ve biyomedikal uygulamaları için mikro/nanoteknoloji alanlarında çalışan doktora sonrası, doktora, yüksek lisans ve lisans öğrencileri de dahil olmak üzere bir grup araştırmacıya liderlik etmektedir. Akademik kariyerine İstanbul Üniversitesi, Moleküler Biyoloji ve Genetik Bölümü'yle başlayan Dr. İnci, lisans eğitiminin bir kısmını Hollanda'nın Groningen Üniversitesi'nde Sokrates öğrencisi olarak tamamlamıştır. Doktora derecesini İstanbul Teknik Üniversitesi, Moleküler Biyoloji Bölümü-Genetik ve Biyoteknoloji Bölümü'nden almıştır. Ayrıca doktora eğitimi esnasında da Avustralya'da New South Wales ve Sidney Teknoloji Üniversiteleri ile ABD'de Harvard Üniversitesi Tıp Fakültesi, Brigham & Women's Hospital ve Harvard-MIT Sağlık Bilimleri ve Teknolojisi Bölümü'nde araştırmacı olarak çalışmıştır. Doktorasını tamamladıktan sonra, Harvard Üniversitesi Tıp Fakültesi, Brigham & Women's Hospital'da ve Stanford Üniversitesi Tıp Fakültesi'nde doktora sonrası çalışmalarını tamamlamıştır. Dr. İnci, biyomedikal mühendisliği, biyoteknoloji ve tıp alanlarında mikro- ve nano-ölçekli platform teknolojileri kullanmaktadır. Özellikle teşhis, kişiye özgü tıp, erken kanser tespiti, biyolojik belirteç keşfi ve adli tıp bilimi için mühendislik, biyoloji, kimya ve malzeme bilimlerini bir araya getirerek, hastalıkların izlenmesi ve biyolojik belirteçlerin analizi için yenilikçi, kullanıcı dostu, yüksek hassasiyet ve spesifiklikte sensör platformları geliştirmeyi amaçlamaktadır. Ayrıca nanoplazmonik sistemler, mikroakışkanlar, biyosensörler, yapay lipit hücre zarları ve ilaç salınım sistemleri gibi birçok uygulama üzerinde çalışmaktadır. Dr. İnci yaptığı çalışmalarını dünyanın en prestijli dergilerinde yayınlamıştır. Araştırma yayınlarının yanı sıra, 4 kitap bölümünün de yayınlanmasına katkıda bulunmuş ve çalışmalarını bir çok ulusal ve uluslararası konferanslarda sunmuştur. Ayrıca, kendisinin araştırma sonuçları ve ürünlerinden 6 adet patenti bulunmaktadır. Dr. İnci'nin çalışmalarının önemi, National Institute of Health, Nature Medicine, Science AAAS, Popular Science, Newsweek, Boston University, Canary Center-Stanford University, Brigham & Women's Hospital, Center for Integration of Medicine and Innovative Technology (CIMIT) ve Epilepsy Foundation gibi uluslararası kuruluşlar tarafından vurgulanmıştır. Bunların yanında, European Molecular Biology Organization-European Science Foundation (EMBO-ESF), American Chemical Society ve TÜBİTAK kuruluşları tarafından kazandığı destek ve bursları da mevcuttur. Dr. İnci, American Association for the Advancement of Science (AAAS), Royal Society of Chemistry (RSC), American Association for Cancer Research (AACR) ve National Postdoctoral Association (NPA) gibi dünyanın en büyük ve prestijli bilim camialarının bir üyesidir.

The American Association for Cancer Research (AACR) announced the launch of an international initiative known as AACR Project Genomics, Evidence, Neoplasia, Information, Exchange (GENIE). The initial phase of the project, which is being conducted in partnership with seven global leaders in genomic sequencing for clinical utility, as well as two informatics partners, will aggregate project members’ clinical-grade sequencing data to improve patient treatment decisions and catalyze clinical and translational research. The seven founding members of the consortium and phase 1 participants are: The Center for Personalized Cancer Treatment, Utrecht, Netherlands; Dana-Farber Cancer Institute, Boston; Institut Gustave Roussy, Villejuif, France; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore; Memorial Sloan Kettering Cancer Center, New York; Princess Margaret Cancer Centre, Toronto; and Vanderbilt-Ingram Cancer Center, Nashville, Tennessee. The two informatics partners are: Sage Bionetworks, Seattle; and cBioPortal, New York.

AACR Survey and Cancer Progress Report 2015 Video

If you followed the news from the recent show of the American Association for Cancer Research (AACR), no doubt you heard about the exciting potential of liquid biopsies. These new blood-based tests, made possible by better tools and analysis techniques, offer a non-invasive way of understanding various cancers. Traditionally, with non-hematological cancers, solid tumor biopsies are obtained through surgical recession or an invasive needle.